150 likes | 329 Views
Access to HIV/AIDS Medicines The 3x5 strategy. WHO/EDM Technical Briefing Seminar 15-19 March 2004. Three by Five. The goal is universal access to anti-retroviral therapy as a human right The target is three million people on treatment by the end of 2005
E N D
Access to HIV/AIDS Medicines The 3x5 strategy WHO/EDM Technical Briefing Seminar 15-19 March 2004
Three by Five • The goal is universal access to anti-retroviral therapy as a human right • The target is three million people on treatment by the end of 2005 • The treatment gap was declared a global health emergency Sept 22nd at UNGA
Pillar 1: WHO and global level activities • 1. Visible WHO leadership and commitment to urgent action to reach the goal of universal access to ART • 2. Locate the rights-based 3x5 initiative within the broader development context • 3. Support all national efforts whilst focusing WHO resources on high-burden and strategic countries to achieve maximal impact of 3x5 initiative • 4. Align and mobilize partner support to achieve 3x5 target at global level Momentum created Country owned process Member States UNAIDS Co-sponsors Other partners
Pillar 2: Country Support Efforts • 5. Secure the key elements required at the national level to deliver the 3x5 target as part of a comprehensive response to HIV/AIDS • 6. Strengthen and support the renewal of health systems and national operational capacity for scaling up ART programs • 7. Strengthen and build human capacity for scaling up ART • 8. Expand capacity of communities to be fully involved in ART program planning and delivery National Medicines Policy (Selection, procurement, regulation, supply chain management, rational use)
Pillar 3: simplified, standardised tools • 9. Simplify and standardize procedures to identify individuals in need of therapy and facilitate entry to ART programs • 10. Simplify and standardize ARV therapy to facilitate adherence and enable rapid scale-up to be implemented • 11. Simplify and standardize tools for tracking ART program performance including drug resistance surveillance Rapid test based approach 4 First-line treatments FDCs and Blisters Standardized M&E Guidelines
Pillar 4: Effective medicines and diagnostics supply • 12. Support country access to , and efficient distribution of high quality, low cost medicines and diagnostics
Pillar 5: Success stories and learning by doing • 13. Build on success • 14. Continuously learn by doing - with ongoing evaluation and analysis of program performance and a focused operational research agenda.
AMDS objectives • Ensure that the supply of quality commodities is never an obstacle to expanding treatment, care and support • Use improved commodity supply to catalyze rapid expansion of treatment, to promote equity, to support prevention
AMDS general principles • Use partners to best capacity • Don’t develop new structures/systems • All partners involved in planning and further expansion • Support all available channels (government, NGOs, insurances)
What the AMDS will doAssist/support a country-driven process…… • Create information hub • Bring together strategic information from existing sources (ensure ease of access) • Develop new tools as needed (self or contracted) • Serve as “one-stop-shop” for specific support • Initiate and act as gateway for information and Technical Assistance by partners inside and outside WHO • Support operational staff • (Recruit), train and support dedicated procurement and supply chain management staff
What the AMDS does not plan to do……… • No procurement itselfbut • Support countries to buy/manage supplies • Direct to appropriate services • ARVs: PQ Procurement agencies • Diagnostics: WHO bulk procurement scheme • No repeat /duplicate effort • Use ongoing work, available expertise and information • No new structures MOH, NGO. • No funding to purchase commodities
Examples of EDM action and guidance on Access to HIV-Related Medicines* • 13th WHO Model List of Essential Medicines, including (since 12th edition including ARVs) • 2nd WHO Model Formulary, including section on ARVs • Pre-qualification of HIV medicines and manufacturers (R&D and generic) • Annual Reports on “Sources and Prices of Selected Drugs and Diagnostics for People Living With HIV/AIDS; jointly with UNICEF, UNAIDS, MSF • Operational Principles for Good Pharmaceutical Procurement – IPC group • Globalization, TRIPS and Access to Pharmaceuticals. WHO Policy Perspectives on Medicines * Available on EDM web site (http://www.who.int/medicines/)
For further information………. Peter Graaff graaffp@who.int